title: Studies of interferences of apomorphine and its metabolites or decomposition products with immunochemical screening tests for legal and illicit drugs after therapeutic doses of apomorphine.
abstract: This study deals with the question of whether apomorphine (CAS 314-19-2; e.g. in Ixense) and its metabolites or decomposition products interfere with the specificity of immunochemical screening tests (immunoassays) for legal and illicit drugs. It was the result of the investigations that after the therapeutic use of apomorphine no relevant false-positive screening findings were observed with the CEDIA (cloned enzyme donor immuno assay) and FPIA (fluorescence polarisation immuno assay) tests, which are commonly encountered in drug-screening programs, when using recommended cut-off values for urine.
authors.affiliation: Institut für Rechtsmedizin, Universität Giessen, Giessen, Germany. harald.f.schuetz@forens.med.uni-giessen.de
authors.forename: Harald
authors.initials: H
authors.lastname: Schütz
authors.forename: Freidoon
authors.initials: F
authors.lastname: Erdmann
authors.forename: Manfred
authors.initials: M
authors.lastname: Risse
authors.forename: Günter
authors.initials: G
authors.lastname: Weiler
mesh_terms: D001058:Apomorphine / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000652:urine*; D015415:Biomarkers / Q000032:analysis; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005189:False Positive Reactions; D016231:Fluorescence Polarization Immunoassay; D006801:Humans; D007120:Immunochemistry; D015813:Substance Abuse Detection / Q000379:methods*
chemical_list: D015415:Biomarkers; D001058:Apomorphine